The U.S. Food and Drug Administration (FDA) has approved Filkri (filgrastim-laha), a biosimilar to Neupogen (filgrastim), to ...

Executive Chair Adam Craig said the company’s near-term focus is centered on advancing mavorixafor in chronic neutropenia, as ...

An initiative of the ECIL-10 updated guidelines on antimicrobial therapy for patients with febrile neutropenia who have a hematologic malignancy or who have had HCT.

This clearance follows four years of regulatory engagement with the FDA to validate AI-native diagnostics in clinical environments. Athelas Home uses neural-network-based cell analysis and computer ...

The findings, published in BJS Open by M. A. Zarog from the Department of Surgery and colleagues, suggest that circulating fibrocyte percentage (CFP) could help improve diagnostic accuracy in a ...

The FDA has accepted the new drug application (NDA) for tirabrutinib (ONO-4059), a highly selective, irreversible, second-generation Bruton tyrosine kinase (BTK) inhibitor developed for the treatment ...

The NDA is supported by data from part A of the phase 2 PROSPECT trial, which evaluated tirabrutinib in 48 adult patients with R/R PCNSL.

Higher baseline monocyte counts, along with preserved basophils and low C-reactive protein, independently predict complete remission on anti-IgE therapy for CSU.

First and only all-oral, fixed-duration regimen designed to provide CLL patients with the potential to experience time off treatment –– Approval expands Genentech’s fixed-duration portfolio by ...

The FDA has approved a first-of-its-kind portable, noninvasive device that delivers alternating electrical fields for the ...

Nkosingiphile Gumede, already serving life sentences for the brutal murder of ANC councillor Sibusiso Maphumulo, has now been ...